Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sweeney

Showing results (681-690 of 762) with videos related to

Pageof 77
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlatesToni K Choueiri, Susanna Jacobus, Joaquim Bellmunt, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2024
Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 TrialDiego A S Toesca, William F Hartsell, Todd A DeWees, et al.
European Urology|March 4, 2019
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysisSarah Burdett, Liselotte M Boevé, Fiona C Ingleby, et al.
Journal of Geriatric Oncology|May 28, 2014
Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancerBrandon A Mahal, David R Ziehr, Ayal A Aizer, et al.
Nature Medicine|January 11, 2022
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Kobe C Yuen, Silke Gillessen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer GroupDarren R Feldman, Anja Lorch, Andrew Kramar, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2004
Benzimidazolone p38 inhibitorsMark A Dombroski, Michael A Letavic, Kim F McClure, et al.
Current Controlled Trials in Cardiovascular Medicine|July 5, 2002
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline CharacteristicsIan Ford, Gerard Jan Blauw, Michael B Murphy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate CancerChristopher J Sweeney, Ivor J Percent, Sunil Babu, et al.
Pageof 77

Showing results (681-690 of 762) with videos related to

Sort By:
Pageof 77
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlatesToni K Choueiri, Susanna Jacobus, Joaquim Bellmunt, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2024
Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 TrialDiego A S Toesca, William F Hartsell, Todd A DeWees, et al.
European Urology|March 4, 2019
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysisSarah Burdett, Liselotte M Boevé, Fiona C Ingleby, et al.
Journal of Geriatric Oncology|May 28, 2014
Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancerBrandon A Mahal, David R Ziehr, Ayal A Aizer, et al.
Nature Medicine|January 11, 2022
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Kobe C Yuen, Silke Gillessen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer GroupDarren R Feldman, Anja Lorch, Andrew Kramar, et al.
Bioorganic & Medicinal Chemistry Letters|March 12, 2004
Benzimidazolone p38 inhibitorsMark A Dombroski, Michael A Letavic, Kim F McClure, et al.
Current Controlled Trials in Cardiovascular Medicine|July 5, 2002
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline CharacteristicsIan Ford, Gerard Jan Blauw, Michael B Murphy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate CancerChristopher J Sweeney, Ivor J Percent, Sunil Babu, et al.
Pageof 77